Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

The convergence of CNS and oncology research amplifies the significance of Oncotelic’s recent intellectual property updates for OT-101. Developed in collaboration with Sapu Bioscience, the expanded ...

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative ...
Morningstar

Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

With Arbor’s lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, progressing into clinical trials, the company continues to focus its research and development efforts on genomic ...
Nasdaq

Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

− Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments for C5 Complement-Mediated Diseases - − Regeneron to Invest $800 ...
Seeking Alpha

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual ...

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and ...
Nasdaq

Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases Regeneron to invest $800 million ...
MarketWatch

Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

The MarketWatch News Department was not involved in the creation of this content. Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell ...